Praxis Precision Medicines to Present at Upcoming December Investor Conferences
Provided By GlobeNewswire
Last update: Dec 3, 2024
BOSTON, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that it will be participating in two upcoming investor conferences in December 2024.
Read more at globenewswire.com
